Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases.
In the recent decade our understanding of the role of the human gut microbiome has been revolutionized by advances in development of molecular methods. Approximately, up to 100 trillion (10(14)) microorganisms per human body colonize the intestinal tract making an additional acquired organ that provides many vital functions to the host. A healthy gut microbiome can be defined by the presence of the various classes of microbes that enhance metabolism, resistance to infection and inflammation, prevention against cancer and autoimmunity and that positively influence so called braingut axis. Diet represents one of the most important driving forces that besides environmental and genetic factors, can define and influence the microbial composition of the gut. Aging process due to different changes in gut physiology (i.e. gastric hypochlorhydria, motility disorders, use of drugs, degenerative changes in enteric nervous system) has a profound effect on the composition, diversity and functional features of gut microbiota. A perturbed aged gut microbiome has been associated with the increasing number of gastrointestinal (e.g. Clostridium difficile infection - CDI) and non-gastrointestinal diseases (metabolic syndrome, diabetes mellitus, fatty liver disease, atherosclerosis etc.). Fecal microbiota transplantation (FMT) is a highly effective method in the treatment of refractory CDI. FMT is the term used when stool is taken from a healthy individual and instilled during endoscopy (colonoscopy or enteroscopy) into a gut of the sick person to cure certain disease. FMT represents an effective therapy in patient with recurrent CDI and the effectiveness of FMT in the prevention of CDI recurrence had reached approx. 90%. There is also an increasing evidence that the manipulation of gut microbiota by FMT represents a promising therapeutic method in patients with inflammatory bowel disease and irritable bowel syndrome. There is also an increased interest in the role of FMT for the treatment of metabolic syndrome and obesity which collectively present the greatest health challenge in the developed world nowadays. Targeting of gut microbiota by FMT represents an exciting new frontier in the prevention and management of gastrointestinal and non-gastrointestinal diseases that awaits further studies in preclinical and clinical settings.
Department of Internal Medicine, Thuringia-Clinic, Teaching Hospital of the University of Jena, Saalfeld, Germany. pkonturek@web.de.
P C
PC
Konturek
Department of Internal Medicine, Thuringia-Clinic, Teaching Hospital of the University of Jena, Saalfeld, Germany.
D
D
Haziri
Department of Physiology, Jagiellonian University Medical College Cracow, Poland.
T
T
Brzozowski
Department of Internal Medicine, Thuringia-Clinic, Teaching Hospital of the University of Jena, Saalfeld, Germany.
T
T
Hess
Department of Internal Medicine, Thuringia-Clinic, Teaching Hospital of the University of Jena, Saalfeld, Germany.
S
S
Heyman
Department of Physiology, Jagiellonian University Medical College Cracow, Poland.
S
S
Kwiecien
Department of Physiology, Jagiellonian University Medical College Cracow, Poland.
S J
SJ
Konturek
Department of Microbiology, Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University, Cracow, Poland.
J
J
Koziel
D000818:Animals; D005243:Feces / Q000382:microbiology*; D005767:Gastrointestinal Diseases / Q000628:therapy*; D000069196:Gastrointestinal Microbiome; D006801:Humans